Beren Therapeutics raised $300 million through new financings as it prepares for an FDA decision later this fall for its rare disease drug candidate. The capital raise is explicitly positioned to help fund launch and ongoing development ahead of the regulatory milestone. The company’s update emphasizes liquidity timing, suggesting a plan to maintain momentum through the late-stage and potential commercialization window once the FDA ruling is made. Details of the raised amount were partially reflected in the excerpt. For rare disease biotech investors, the move signals continued ability for disease-focused companies to secure substantial non-dilutive or dilutive funding when a near-term FDA catalyst is on the calendar. As the fall decision approaches, additional clarity on label scope, endpoints, and access strategy will likely determine whether the cash infusion translates into an efficient transition to payer-ready evidence generation.